On this page of StockholderLetter.com we present the latest annual shareholder letter from AMICUS THERAPEUTICS, INC. — ticker symbol FOLD. Reading current and past FOLD letters to shareholders can bring important insights into the investment thesis.
• 
4/24/2025 Letter Continued (Full PDF)
•
4/26/2023 FOLD Stockholder Letter
• 4/24/2024 FOLD Stockholder Letter
• More "Biotechnology" Category Stockholder Letters
•
FOLD Benford's Law Stock Score = 54
4/24/2025 Letter Continued (Full PDF)
•
4/26/2023 FOLD Stockholder Letter•
4/24/2024 FOLD Stockholder Letter•
More "Biotechnology" Category Stockholder Letters•
FOLD Benford's Law Stock Score = 54FOLD Shareholder/Stockholder Letter Transcript:
An extraordinary story in rare disease. 2024 ANNUAL REPORT About Amicus OUR MISSION To develop and deliver transformative medicines for people living with rare diseases OUR VISION To become one of the leading rare disease-focused biotech companies Amicus Therapeutics 2024 Annual Report To our shareholders Bradley L. Campbell President and Chief Executive Officer 2024 represented a truly pivotal year in the 20-plus history of Amicus. On behalf of our patient-centered team, I am delighted to share some of the highlights of this past year with you, and our excitement about what s ahead for this special company. As we closed 2024, we reached several important milestones for Amicus. First and most importantly, we surpassed 3,000 people living with a rare disease taking an Amicus medicine. We also delivered more than $500 million in annual revenue and achieved nonGAAP pro tability in 2024. We accomplished all of this because of our laser focus on our mission to develop and deliver transformative medicines for people living with rare diseases. Amicus stands out as a unique story in the biotech space both in terms of what we have accomplished, and what we are on track to do. OUR STRATEGIC PRIORITIES FOR 2025 This year we are focused on several key priorities, including: 1. Driving continued double-digit revenue growth through the uptake of both Galafold and Pombiliti + Opfolda 2. Advancing our ongoing studies to broaden indications and reinforce our leadership in Fabry and Pompe disease 3. Maintaining our nancial discipline as we continue on our path to GAAP pro tability We have the foundation that we need to deliver sustainable long-term growth: two approved medicines with compelling value propositions in growing rare disease categories; strong intellectual property for both of these medicines; a leverageable commercial organization; and an increasingly strong nancial position. With the momentum we now have across our global business, we anticipate that we will deliver $1 billion in total revenue in 2028. Our growth trajectory, our rare-disease focus, and our nancial discipline will enable us to deliver double-digit growth and patient impact in 2025 and for years to come, and to invest in continued innovation in Fabry and Pompe disease and business development. A VISION FOR THE FUTURE Amicus is well positioned to become one of the leading global rare disease companies and represents a rare blend of patient focus, demonstrated commercial performance, sustainable long-term growth, and nancial strength. Within our two disease areas, there are more than 10,000 diagnosed patients and more than 100,000 undiagnosed patients. We re resolute in our commitment to reach these individuals, and our aim is to exceed expectations in the number of lives we reach. This will be accomplished by executing on our commercial launches, fully leveraging our global infrastructure and capabilities, and developing innovative new medicines all while staying true to who we are, a patient-focused rare disease company. With a clear path forward, we are con dent in our ability to create lasting value for patients and shareholders alike. Thank you for your continued support as we enter our next phase of success. Sincerely, SUSTAINABLE LONG-TERM GROWTH We re proud of the progress that we ve made, and excited about what s ahead in our journey to reach more and more people around the world with our transformative medicines. Bradley Campbell Amicus Therapeutics 2024 Annual Report A Rare Company Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel, high-quality medicines for people living with rare diseases. (As of December 31, 2024) $528M Net Product Sales 2 Approved Therapies ~500 Galafold and Pombiliti + Opfolda Dedicated Employees Globally Global Footprint in Leverageable 20+ Countries Global Commercial Organization Non-GAAP Pro tability Achieved in FY 20241 1. Amicus de nes non-GAAP Net (Loss) Income as GAAP Net (Loss) Income excluding the impact of share-based compensation expense, changes in fair value of contingent consideration, loss on impairment of assets, depreciation and amortization, acquisition related income (expense), loss on extinguishment of debt, restructuring charges and income taxes Amicus Therapeutics 2024 Annual Report Reaching P Patients atie ents he e Globe Gllobe be Across the Amicus is a global organization, united by a passion for making a difference International HQ MARLOW, UNITED KINGDOM Global HQ PRINCETON, NJ NETHERLANDS GERMANY CANADA ITALY SPAIN JAPAN FRANCE AUSTRALIA Our global footprint spans over 20 countries, including our global headquarters in Princeton, NJ and international headquarters in Marlow, UK. Additional international office locations include Australia, Canada, France, Japan, Germany, Italy, the Netherlands, and Spain. Amicus Therapeutics 2024 Annual Report